American College of Cardiology 71st Scientific Sessions: Science Preview, April 4, 2022

At ACC 2022 on Sunday, 4-2, look for studies on icosapent ethyl and alirocumab, landmark research on HFrEF, and a novel anticoagulant for atrial fibrillation.

On the final day of ACC 2022, check out late-breaking clinical trials during 3 different sessions.

A few higlights: Edoxaban vs DAPT post-TAVR, finerenone and cardiorenal outcomes in special CVD populations, canakinumab and residual inflammatory risk, and a report on an international ACC program to improve treatment for STEMI.

Saturday, April 2, 2022 Late Breaking Clincial Trials

Sunday, April 3, 2022 Late Breaking Clincial Trials

More News from ACC on Patient Care

Related Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
Related Content
© 2023 MJH Life Sciences

All rights reserved.